DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced the publication of a paper in the October 2008 issue of the Journal of Immunotherapy demonstrating that the Company’s process of maturing dendritic cells (DC) electroporated with antigen-encoded messenger RNA (mRNA) is capable of driving long-term, stable expansion of cytolytic antigen-specific T cells that express effector/memory phenotype. These T cells also exhibited much higher functional activity, suggesting improved T cell avidity. This approach is part of the Company’s Arcelis™ technology, a proprietary platform for creating personalized immunotherapies for HIV, other infectious diseases, and cancer.
